Navigation Links
Caliper's Microfluidic Technologies Enable 510(k) Approved Multiplexed Immunoassay System for Liver Cancer Risk Assessment
Date:3/3/2011

HOPKINTON, Mass., March 3, 2011 /PRNewswire/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP) today announced that its licensee Wako Pure Chemical Industries, through its Wako Diagnostics division, has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its uTASWako® i30 Immunoanalyzer and AFP-L3 and DCP Assays, which are used to assess liver cancer risk in patients with chronic liver disease.  The i30 Immunoanalyzer, which incorporates Caliper's microfluidic LabChip® technologies, utilizes microfluidics to integrate sampling, mixing, separation and detection of up to six analytes.  The system is currently marketed in Japan by Wako as an in vitro diagnostic (IVD) platform.

"Wako was an early adopter of Caliper's microfluidic LabChip technology and the 510(k) approval for the uTASWako i30 Immunoanalyzer instrument and associated diagnostic tests is an important milestone in the validation of microfluidics as a valuable platform for diagnostics," said Kevin Hrusovsky, President and CEO of Caliper Life Sciences.  "Caliper's microfluidic technologies are playing an increasing role in diagnostics through our licensees such as Wako, Becton Dickinson, Canon, as well as through Caliper's own direct channel.  Partnerships, like the recently announced Sony DADC collaboration, have uniquely positioned Caliper to develop breakthrough diagnostic solutions based on high volume plastic consumable manufacturing capabilities."

Caliper recently announced the LabChip Dx multiplexed reader, which utilizes innovative microfluidics technology to perform reproducible, high-resolution, electrophoretic separations for analyzing multiplex PCR products.  Developed in collaboration with Seegene, the LabChip Dx is based on the same approach that has become the standard, microfluidic based, electrophoretic separation platform in life sciences research, enabling high throughput, multiplex, cost effective sample processing for discovery and validation of molecular and companion diagnostics.  The cost-effective approach of Caliper's robust microfluidics technology explains its high rate of adoption among research laboratories around the world.  

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to develop life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results that translate into potential cures for a range of diseases. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, molecular imaging technologies, and discovery & development outsourcing solutions. For more information please visit www.caliperLS.com.

Caliper and LabChip are registered trademarks of Caliper Life Sciences, Inc.  uTASWako is a registered trademark of Wako Pure Chemical Industries.  Sony and DADC are registered trademarks of Sony Corporation.  


'/>"/>
SOURCE Caliper Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. RainDance Technologies to Present Sequence Enrichment Using Droplet-Based Microfluidics Workshop at ASHG 2008
2. GEN Reports on Growing Reliance on Microfluidics Technology
3. Microfluidics Expands Distributorship in Japan with Exclusive POWREX Partnership to Meet Increased Demand in Pharmaceutical, Biotechnology and Energy Industries
4. Nanopoint Applies CE Mark to Its cellTRAY(R) Imaging and Microfluidics Systems
5. MicroFluidic Systems (MFSI) Receives Patent for Method to Selectively Process Different Biological Cell Types for Analysis.
6. Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization
7. Microfluidics International Corporation to Report Second Quarter 2009 Financial Results on August 11, 2009
8. Microfluidics International Corporation Announces Second Quarter 2009 Financial Results
9. Microfluidics International Corporation to Report Third Quarter 2009 Financial Results on November 2, 2009
10. Microfluidics International Corporation Announces Third Quarter 2009 Financial Results
11. Microfluidics Chairman James N. Little, Ph.D., Announces Retirement from Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... BEACH, Fla. , Feb. 16, 2017 /PRNewswire/ ... company revolutionizing the development of liquid biopsy tests ... has entered into an exclusive license agreement with ... distribute MDNA,s proprietary liquid biopsy test for prostate ... South Korea . This is the ...
(Date:2/16/2017)... --  Biostage, Inc. (Nasdaq: BSTG ), ... organ implants to treat cancers and other life-threatening conditions ... closing on February 15, 2017 of its previously announced ... warrants to purchase 20,000,000 shares of common stock, for ... priced at $0.40 per share of common stock, with ...
(Date:2/16/2017)...  Champions Oncology, Inc. (NASDAQ: CSBR ), ... advanced technology solutions and products to personalize the development ... of new cohorts of PDX models to their existing ... Champions, product line in hepatocellular cancer, breast cancer, castrate ... non-small cell lung cancer (including EGFR mutation; ALK/ROS1 positive) ...
(Date:2/16/2017)... NEW YORK , Feb. 16, 2017 /PRNewswire/ ... their $7M Series B financing, adding an additional $3M ... led by Mesa Verde Venture Partners and other strategic ... be directed towards further accelerating commercial adoption of their ... profiling test and expanding the Paradigm cancer registry. ...
Breaking Biology Technology:
(Date:1/19/2017)... SANTA CLARA, Calif. , Jan. 19, 2017 ... Valley company enhancing user experience and security for ... provider of next-generation payment processing systems and cybersecurity ... assist more banks, enterprises and financial institutions worldwide ... As part of the end-to-end secure user authentication ...
(Date:1/18/2017)... Jan. 18, 2017 MedNet Solutions ... supports the entire spectrum of clinical research, is ... record-breaking year for the organization in terms of ... MedNet,s eClinical products and services. The company,s exceptional ... success of iMedNet ™ ...
(Date:1/12/2017)... , Jan. 12, 2017  Trovagene, Inc. (NASDAQ: ... (ctDNA) technologies, today announced that it has signed agreements ... and the Middle East ... milestone marks the first wave of international distribution agreements ... and blood samples. The initial partners will ...
Breaking Biology News(10 mins):